JP2019163319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019163319A5 JP2019163319A5 JP2019104081A JP2019104081A JP2019163319A5 JP 2019163319 A5 JP2019163319 A5 JP 2019163319A5 JP 2019104081 A JP2019104081 A JP 2019104081A JP 2019104081 A JP2019104081 A JP 2019104081A JP 2019163319 A5 JP2019163319 A5 JP 2019163319A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- region
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 40
- 239000007864 aqueous solution Substances 0.000 claims 20
- 102000004965 antibodies Human genes 0.000 claims 16
- 108090001123 antibodies Proteins 0.000 claims 16
- 229920002574 CR-39 Polymers 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drugs Drugs 0.000 claims 6
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 1
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 230000002209 hydrophobic Effects 0.000 claims 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021081392A JP7162695B2 (ja) | 2013-11-21 | 2021-05-13 | 抗体-薬物コンジュゲート凍結乾燥製剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361907001P | 2013-11-21 | 2013-11-21 | |
US61/907,001 | 2013-11-21 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016533019A Division JP6590803B2 (ja) | 2013-11-21 | 2014-11-21 | 抗体−薬物コンジュゲート凍結乾燥製剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021081392A Division JP7162695B2 (ja) | 2013-11-21 | 2021-05-13 | 抗体-薬物コンジュゲート凍結乾燥製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019163319A JP2019163319A (ja) | 2019-09-26 |
JP2019163319A5 true JP2019163319A5 (ru) | 2020-03-19 |
Family
ID=51947368
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016533019A Active JP6590803B2 (ja) | 2013-11-21 | 2014-11-21 | 抗体−薬物コンジュゲート凍結乾燥製剤 |
JP2019104081A Pending JP2019163319A (ja) | 2013-11-21 | 2019-06-04 | 抗体−薬物コンジュゲート凍結乾燥製剤 |
JP2021081392A Active JP7162695B2 (ja) | 2013-11-21 | 2021-05-13 | 抗体-薬物コンジュゲート凍結乾燥製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016533019A Active JP6590803B2 (ja) | 2013-11-21 | 2014-11-21 | 抗体−薬物コンジュゲート凍結乾燥製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021081392A Active JP7162695B2 (ja) | 2013-11-21 | 2021-05-13 | 抗体-薬物コンジュゲート凍結乾燥製剤 |
Country Status (7)
Country | Link |
---|---|
US (3) | US10617764B2 (ru) |
EP (1) | EP3071237A1 (ru) |
JP (3) | JP6590803B2 (ru) |
KR (1) | KR102372245B1 (ru) |
CN (2) | CN113521016A (ru) |
MX (1) | MX2016006488A (ru) |
WO (1) | WO2015075201A1 (ru) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011267106B2 (en) * | 2010-06-15 | 2015-05-14 | Genmab A/S | Human antibody drug conjugates against tissue factor |
US10617764B2 (en) * | 2013-11-21 | 2020-04-14 | Genmab A/S | Lyophilized anti-tissue factor antibody-drug conjugates |
EP3319597B1 (en) * | 2015-07-10 | 2021-02-17 | Byondis B.V. | Compositions comprising antibody-duocarmycin drug conjugates |
EP3919081A1 (en) | 2015-09-11 | 2021-12-08 | Genmab A/S | Dosing regimens for anti-tf-antibody drug-conjugates |
WO2017091745A1 (en) | 2015-11-25 | 2017-06-01 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
SG11201805534TA (en) * | 2016-01-13 | 2018-07-30 | Genmab As | Formulation for antibody and drug conjugate thereof |
US11352423B2 (en) * | 2016-06-27 | 2022-06-07 | Morphosys Ag | Anti-CD19 antibody formulations |
CN106938051B (zh) * | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
SG11202006400UA (en) | 2018-01-04 | 2020-08-28 | Iconic Therapeutics Inc | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
TWI811335B (zh) * | 2018-04-13 | 2023-08-11 | 美商建南德克公司 | 穩定抗cd79b免疫結合物調配物 |
JP7460608B2 (ja) | 2018-05-07 | 2024-04-02 | ジェンマブ エー/エス | 抗pd-1抗体と抗組織因子抗体-薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
AU2019266205A1 (en) | 2018-05-07 | 2020-10-22 | Genmab A/S | Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate |
AU2019321442A1 (en) * | 2018-08-16 | 2021-02-11 | Genmab A/S | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
TW202034958A (zh) | 2018-10-30 | 2020-10-01 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法 |
PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
KR20220058555A (ko) * | 2019-08-15 | 2022-05-09 | 실버백 테라퓨틱스, 인크. | 벤즈아제핀 접합체의 제형 및 이의 용도 |
MX2022005222A (es) | 2019-11-07 | 2022-06-08 | Genmab As | Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco. |
TW202131954A (zh) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法 |
BR112022025105A2 (pt) | 2020-06-29 | 2023-01-17 | Genmab As | Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco |
CN116635077A (zh) * | 2020-11-10 | 2023-08-22 | 赛诺菲 | Ceacam5抗体-药物缀合物制剂 |
WO2023213960A1 (en) | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
EP0417193B1 (en) * | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
WO1994005328A1 (en) * | 1992-08-28 | 1994-03-17 | The Scripps Research Institute | Inhibition of tumor metastasis via neutralization of tissue factor function |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
JPH11510170A (ja) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
AU740284B2 (en) | 1997-06-13 | 2001-11-01 | Genentech Inc. | Stabilized antibody formulation |
EP1336410A4 (en) | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
KR100913714B1 (ko) | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
AU2003247686A1 (en) | 2002-07-02 | 2004-01-23 | Smithkline Beecham Corporation | A novel stable formulation |
AU2003242506A1 (en) * | 2002-07-12 | 2004-02-02 | Novo Nordisk A/S | Tf antagonist |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
TR201808801T4 (tr) | 2003-02-10 | 2018-07-23 | Biogen Ma Inc | İmmünoglobulin formülasyonu ve bunun hazırlanış yöntemi. |
US7605235B2 (en) * | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2006014965A2 (en) | 2004-07-27 | 2006-02-09 | Human Genome Sciences, Inc. | Pharmaceutical formulation and process |
US20070196364A1 (en) * | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2007034443A (ja) * | 2005-07-22 | 2007-02-08 | Konica Minolta Business Technologies Inc | 画像形成システム、画像形成装置及び画像形成処理方法 |
MX336033B (es) | 2005-08-03 | 2016-01-07 | Immunogen Inc | Formulaciones de inmunoconjugado. |
CN101237881B (zh) * | 2005-08-03 | 2015-04-22 | 伊缪诺金公司 | 免疫偶联物剂型 |
KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
CN101677987A (zh) * | 2007-06-22 | 2010-03-24 | 赛多斯有限责任公司 | 不含吐温80的多西他赛的增溶制剂 |
KR20090001217A (ko) * | 2007-06-29 | 2009-01-08 | 삼성전자주식회사 | 미싱 노즐 검출방법 및 이를 이용하는 잉크젯 프린트 헤드 |
JP4824710B2 (ja) * | 2008-02-08 | 2011-11-30 | 国立清華大学 | グラフト共重合体およびブロック共重合体の多機能混合ミセルならびにその製造方法 |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
JP5005023B2 (ja) * | 2009-12-25 | 2012-08-22 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 読出し及び書込み命令の混在するコマンド列を受け取った場合の最適な書込みを実行するリニア記録方式の装置、その方法、及びプログラム。 |
EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
ES2722201T3 (es) * | 2010-03-22 | 2019-08-08 | Hoffmann La Roche | Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas |
AU2011267106B2 (en) * | 2010-06-15 | 2015-05-14 | Genmab A/S | Human antibody drug conjugates against tissue factor |
US10617764B2 (en) * | 2013-11-21 | 2020-04-14 | Genmab A/S | Lyophilized anti-tissue factor antibody-drug conjugates |
EP3919081A1 (en) | 2015-09-11 | 2021-12-08 | Genmab A/S | Dosing regimens for anti-tf-antibody drug-conjugates |
-
2014
- 2014-11-21 US US15/038,235 patent/US10617764B2/en active Active
- 2014-11-21 JP JP2016533019A patent/JP6590803B2/ja active Active
- 2014-11-21 KR KR1020167016066A patent/KR102372245B1/ko active IP Right Grant
- 2014-11-21 MX MX2016006488A patent/MX2016006488A/es unknown
- 2014-11-21 WO PCT/EP2014/075326 patent/WO2015075201A1/en active Application Filing
- 2014-11-21 EP EP14802428.4A patent/EP3071237A1/en active Pending
- 2014-11-21 CN CN202110607250.1A patent/CN113521016A/zh active Pending
- 2014-11-21 CN CN201480073804.2A patent/CN106163567B/zh active Active
-
2019
- 2019-06-04 JP JP2019104081A patent/JP2019163319A/ja active Pending
-
2020
- 2020-01-14 US US16/742,158 patent/US20200246477A1/en not_active Abandoned
-
2021
- 2021-05-13 JP JP2021081392A patent/JP7162695B2/ja active Active
-
2022
- 2022-12-13 US US18/065,196 patent/US20240091373A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019163319A5 (ru) | ||
US10758556B2 (en) | Anthracycline-based antibody drug conjugates having high in vivo tolerability | |
JP6333882B2 (ja) | 抗体−薬剤コンジュゲート | |
KR100812658B1 (ko) | 향상된 세포독성 및 수율의 항-이지에프알브이 3,에스씨에프브이에스, 이에 기초한 면역독소, 및 이의 이용방법 | |
ES2788864T3 (es) | Conjugados de anticuerpo-fármaco e inmunotoxinas | |
JP6616776B2 (ja) | 抗体−薬物複合体及び免疫毒素 | |
KR20160079890A (ko) | 항체-약물 접합체 동결건조 제제 | |
JP2014050409A (ja) | 高い結合親和性を有する免疫結合体 | |
JP6585600B2 (ja) | C末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法 | |
JP2020509031A5 (ru) | ||
US20200222552A1 (en) | Pharmaceutical formulations and methods of use thereof | |
WO2002043661A3 (en) | Recombinant anti-cd30 antibodies and uses thereof | |
AU2013209512B2 (en) | Surrobody cojugates | |
WO2004064787A3 (en) | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus | |
KR102399028B1 (ko) | 이중-특이적 항원-결합 폴리펩티드 | |
RU2020112280A (ru) | Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение | |
IL273384B2 (en) | Methods to prevent methionine oxidation in immune conjugates | |
US20170326252A1 (en) | Nanoparticles for Delivery of Agents to Glioblastoma Tumors | |
US20240091372A1 (en) | Anti-doppel antibody drug conjugates | |
CN113795513A (zh) | 抗外周淋巴结地址素抗体及其用途 | |
RU2023123071A (ru) | Способы предотвращения окисления метионина в иммуноконъюгатах |